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Edited by Gianni CesareniAbstract The multi-domain protein PIST (protein interacting
speciﬁcally with Tc10) interacts with the SSTR5 (somatostatin
receptor 5) and is responsible for its intracellular localization.
Here, we show that PIST is expressed in pancreatic b-cells
and interacts with SSTR5 in these cells. PIST expression in
MIN6 insulinoma cells is reduced by somatostatin (SST). After
stimulation with SST, SSTR5 undergoes internalization together
with PIST. MIN6 cells over-expressing PIST display enhanced
glucose-stimulated insulin secretion and a decreased sensitivity
to SST-induced inhibition of insulin secretion. These data sug-
gest that PIST plays an important role in insulin secretion by
regulating SSTR5 availability at the plasma membrane.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Somatostatin (SST) is a peptide hormone with a wide spec-
trum of biological actions. The isoforms, SST-14 and SST-28,
consist of 14 and 28 amino acids, respectively. In the endocrine
pancreas SST secreted from d-cells inhibits insulin and gluca-
gon secretion [1]. SST acts via ﬁve somatostatin receptors
(SSTR1–5), which belong to the G-protein coupled receptor
(GPCR) family [2]. SSTR5 has a 10-fold higher aﬃnity for
SST-28 as compared to SST-14 [3]. It is believed that SST-28
via SSTR5 inhibits the release of insulin from b-cells, whereas
SST-14 via the SSTR2 mediates the inhibition of glucagon re-
lease from a-cells [4,5]. In insulin secreting cells, SST inhibitsAbbreviations: CFTR, cystic ﬁbrosis transmembrane regulator; EGFP,
enhanced green ﬂuorescent protein; GPCR, G-protein coupled recep-
tor; GST, glutathione S-transferase; hGH, human growth hormone;
PDZ, PSD-95/discs large/zonula occludens 1; PIST, protein interacting
speciﬁcally with Tc10; SST, somatostatin; SSTR5, somatostatin recep-
tor 5
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doi:10.1016/j.febslet.2005.10.009glucose-induced electrical activity via activation of ATP-sensi-
tive K+-channels [6]. SST can also exert a direct inhibitory ac-
tion on exocytosis of the insulin-containing granules [7].
In islets the subcellular localization of somatostatin recep-
tors is under control of glucose and other insulin secretagogues
[8]. Stimulation of islets with high glucose concentrations in-
duces immediate recruitment of SSTRs from intracellular
organelles to the plasma membrane. The SSTR translocation
renders b-cells more sensitive to SST-induced inhibition of
insulin secretion and, thus, can play an important role in
paracrine regulation of insulin secretion by SST [9].
Intracellular traﬃcking as well as signalling by GPCRs are
modulated by intracellular binding partners [10,11]. For
SSTR5, we have recently shown that it binds to the PSD-95/
discs large/zonula occludens 1 (PDZ) domain protein PIST
(PDZ domain containing protein interacting speciﬁcally with
Tc10) [12]. PIST is associated with the Golgi-apparatus and
regulates the post-synthetic traﬃcking of the cystic ﬁbrosis
transmembrane regulator (CFTR) and other transmembrane
proteins [13–15]. In HEK293 cells, the C-terminal PDZ ligand
of the SSTR5 is required for post-endocytic sorting of the
receptor from the Golgi-apparatus to the plasma membrane
[14]. Here, we show that PIST is expressed in pancreatic b-
cells, where it interacts with SSTR5. Interaction of these two
proteins modulates SSTR5 receptor signaling and paracrine
regulation of insulin secretion by SST.2. Materials and methods
2.1. Islet isolation and MIN6 culture
Pancreatic islets were isolated from male Wistar rats (250–300 g,
Charles River Laboratories, Sulzfeld, Germany) as described [16].
MIN6 cells were cultured in DMEM medium (Invitrogen,
Carlsbad, CA, USA) supplemented with 10% (v/v) heat-inactivated
fetal calf serum, 100 IU/ml penicillin and 100 lg/ml streptomycin
(Invitrogen).
2.2. Fusion proteins and antibodies
Expression of glutathione S-transferase (GST) fusion proteins and
puriﬁcation using glutathione sepharose (AP Biotech, Freiburg, Ger-
many) was performed as described by the manufacturer. The rabbit
anti-PIST antibody, guinea-pig anti-PIST antibody [12] and rabbit
anti-SSTR5 antibody [17] have been described before. Rabbit anti-
insulin was obtained from Santa Cruz (H-86, Santa Cruz, CA,
USA), Bip/GRP78, GM130 and annexin-II antibodies were obtainedblished by Elsevier B.V. All rights reserved.
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COP antibodies were obtained from Aﬃnity BioReagents (Golden,
CO, USA).
2.3. Expression constructs
A fusion construct of the coding region of PIST with enhanced green
ﬂuorescent protein (EGFP) has been described before [12]. The coding
region of the human growth hormone (hGH) was cloned into
pCDNA3.1 (Invitrogen).
2.4. Pull-down assay
MIN6 cells were lyzed in RIPA-lysis buﬀer (50 lM Tris–HCl, pH
8.0, 150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 5 mM EDTA,
0.1% SDS, 0.2 mM phenylmethylsulfonyl ﬂuoride, 1 lg/ml pepstatin,
and 10 lg/ml leupeptin). Lysates were centrifuged (10 min;
10000 · g). GST fusion proteins were prepared and bound to glutathi-
one beads (10 lg protein per individual experiment). The beads were
incubated with cell lysate from the MIN6 cells for 2 h at 4 C. Samples
were precipitated by centrifugation and supernatants removed. After
extensive washing of the beads with RIPA-lysis buﬀer, lysate and pre-
cipitate were analyzed by Western blotting using anti-PIST antibody.
2.5. Cell fractionation
MIN6 cells (equal cell numbers for each experiment) were lyzed in
isotonic buﬀer (20 mM HEPES–HCl, pH 7.4, 1 mM MgCl2, 1 mM
EGTA, and 250 mM sucrose). Nuclei and cellular debris were removed
by centrifugation (1100 · g, 5 min, 4 C). The supernatant was applied
on top of a discontinuous sucrose gradient (0.6–2.0 M sucrose in 0.2 M
steps in lysis buﬀer) and centrifuged (100000 · g, 20 h, 4 C). Fractions
(8 lg protein) were characterized for subcellular organelle distribution
as described previously [18].
2.6. Immunocytochemistry
MIN6 cells and dispersed islets cells were ﬁxed with 4% paraformal-
dehyde in PBS. After blocking (5% normal goat serum, 2% BSA, 0.1%
Triton X-100 in TBS) for 1 h at room temperature cells were incubated
with guinea pig anti-PIST (1:1000) and anti-insulin (1:1000) for 2 h at
room temperature, followed by Cy3- or Cy2-conjugated secondary
antibodies (1:500). Immunostaining was visualized by confocal micros-
copy using a Zeiss LSM 410 microscope (Zeiss, Jena, Germany).
2.7. PIST protein expression
MIN6 cells were cultured for two days in DMEM medium contain-
ing 3 mM glucose with or without 1 lM SST-28. Cells were lyzed with
RIPA-lysis buﬀer and PIST protein levels were analyzed by immuno-
blotting.
2.8. Insulin secretion measurement
MIN6 cells seeded in 96-well plates (30,000 cells per well) were cul-
tured for three days. Cells were starved 1 h in Earles Balanced Salt
Solution (EBSS; Invitrogen) containing 1% BSA and no glucose. Mea-
surements of insulin secretion were then performed in EBSS at indi-
cated glucose concentrations and with substances of interest. Insulin
in the supernatant was analyzed by ELISA.2.9. Insulin and human growth hormone secretion and content
measurement
MIN6 cells were co-transfected with expression vectors for EGFP-
PIST (or EGFP alone) and human growth hormone (hGH) using
the The Nucleofector Device (Amaxa GmbH, Ko¨ln, Germany).
Transfected cells were seeded in 96-well plates (40,000 cells per well)
and cultured for two days. Secretion measurements were performed
as described above. Secreted hGH was detected in culture supernatants
using the hGH ELISA (Roche, Mannheim, Germany). For measure-
ment of the cellular hGH content, cells were lyzed (20 mM Tris–
HCl, pH 7.4, 1% Triton X-100) before ELISA.2.10. Statistical analysis
Results are presented as mean values ± S.E.M. for indicated number
of experiments. Statistical signiﬁcance was evaluated using Students t-
test for one-tailed unpaired data.3. Results
MIN6 cells express PIST, as detected by a strong immunoﬂuo-
rescence signal.Thebulkof thePIST-speciﬁc signalwas co-local-
ized with insulin. In addition, the insulin antibody (which does
not diﬀerentiate between pro-insulin and insulin) labels some
vesicular structures (presumably secretory granules) which do
not contain PIST (arrows in Fig. 1). The co-localization of PIST
and insulin is likely tooccur in theGolgi-apparatus and is consis-
tent with the previous observation of PIST localization in this
cell-compartment [13]. This was conﬁrmed by co-staining for
theGolgi-speciﬁcmarker,bCOP.Also, inprimary ratpancreatic
b-cells, PIST was detected in all islet cells examined. In b-cells
PIST was co-localized with insulin (Fig. 1).
The identity of the immunoreactive signal in MIN6 cells was
further conﬁrmed by Western blot analysis as well as by a pull-
down experiment using a GST fusion protein of the SSTR5 C-
terminus. We have previously shown that SSTR5 interacts
with PIST via the C-terminal PDZ ligand motif [12]. The
SSTR5 fusion protein (or GST control protein) was bound
to a glutathione matrix and incubated with MIN6 cell lysate.
PIST was detected in the lysate and was strongly enriched in
the eluate from the SSTR5-GST matrix but not from the con-
trol GST matrix (Fig. 2A). Thus, PIST is present in MIN6 cells
and can interact speciﬁcally with the C-terminus of SSTR5.
Subcellular fractionation by gradient centrifugation [18] re-
vealed that PIST was abundant in a number of fractions of
light and medium density, whereas SSTR5 was speciﬁcally
conﬁned to fraction 2, which was characterized as the plasma
membrane-associated fraction (Fig. 2B). After treatment of
cells with 1 lM SST-28 for 30 min, both PIST and SSTR5 relo-
cated to the heaviest fraction (Fig. 2C), which displayed inten-
sive staining with antibody against LAMP-2 (Fig. 2D), a
lysosome marker. These data suggest that after treatment with
SST-28, the SSTR5 is internalized and targeted into lysosomes,
possibly due to its association with PIST.
We also examined whether activation of SSTR5 inﬂuences
expression levels of PIST. Treatment of MIN6 cells with
1 lM SST-28 for 48 h reduced PIST expression levels by 55%
when compared to control cells (Fig. 3).
SST inhibits insulin secretion via SSTR5 in pancreatic b-
cells [4]. We examined the eﬀects of SST-28, which preferen-
tially activates SSTR5, on glucose-induced insulin secretion
in MIN6 cells. Raising glucose concentration produced the
expected increase in insulin secretion (Fig. 4A). SST-28 (5
and 50 nM) abolished this increase in insulin secretion,
whereas basal insulin secretion was not aﬀected by SST-28.
In order to elucidate the role of PIST in SSTR5 signalling,
we analyzed glucose-induced insulin secretion in MIN6 cells
over-expressing PIST. Cells were transfected with a PIST-
EGFP expression vector; overexpressed PIST-EGFP was
localized in MIN6 cells in a pattern very similar to that of
the endogenous PIST, i.e., co-localized with endogenous
insulin (Fig. 4B). In order to evaluate hormone secretion
only from cells, which were transfected with expression vec-
tors, we co-transfected MIN6 cells with a vector coding for
hGH. In this set-up, glucose-induced secretion of hGH was
measured as a surrogate for insulin secretion [19]. No diﬀer-
ence in basal hGH secretion was observed between EGFP
and PIST-EGFP expressing MIN6 cells (Fig. 4C). However,
cells expressing PIST-EGFP displayed a signiﬁcant increase
in glucose-induced hGH secretion as compared to glucose-
Fig. 1. MIN6 cells (upper, middle panels) or cells obtained by dispersing rat pancreatic islets (lower panel) were stained with anti-PIST, anti-b COP
and anti-insulin antibodies as indicated. The merged pictures (right) display co-localization of insulin with PIST or bCOP, respectively. Arrows
indicate vesicular labelling for insulin which is not coincident with PIST staining.
W. Wente et al. / FEBS Letters 579 (2005) 6305–6310 6307induced insulin secretion in cells transfected with the empty
pEGFP control vector (Fig. 4C). In addition, SST-28 was
found to be less potent in the inhibition of glucose-induced
hGH secretion in cells expressing PIST-EGFP. Whereas
5 nM SST-28 completely inhibited the increase in hGH
secretion induced with 20 mM glucose in mock transfected
cells, the same concentration of the hormone produced only
50% inhibition of glucose-induced insulin secretion in cells
over-expressing PIST (Fig. 4C).
The alleviation of SST-28 induced inhibition of hormone
secretion by PIST overexpression suggests that PIST regulates
insulin secretion by interfering with SSTR5 signalling. To fur-
ther examine the role of SSTR5 in insulin secretion in MIN6
cells, we studied the eﬀects of the speciﬁc SSTR5 antagonist
BIM23056 [20]. Cells were treated with 1 lM BIM23056 for
1 h and insulin secretion was measured (Fig. 5). In cells treated
with BIM23056, SST-28 does not inhibit insulin secretion indi-
cating the eﬃciency of the antagonist in blocking signalling
through SSTR5. Interestingly, cells treated with BIM23056
in the absence of SST-28 demonstrated an increase in glu-
cose-induced insulin secretion similar to that in cells over-
expressing PIST (Fig. 5). Taken together these data suggest
that inhibition of SSTR5 activity can explain the increase in
glucose-induced hormone secretion observed in MIN6 cells
over-expressing PIST-EGFP.4. Discussion
SSTR5 is known to inhibit glucose-induced insulin secretion
in b-cells when activated by SST-28. SSTR5 deﬁcient mice
show increased basal and glucose-stimulated insulin secretion
implying this receptor subtype in the paracrine regulation of
insulin secretion by SST [5]. In islets, changes in plasma mem-
brane SSTR concentration and receptor traﬃcking was sug-
gested to be important for eﬃciency of paracine regulation
of insulin secretion with SST [9]. Here, we show that PIST reg-
ulates SSTR5 signalling in b-cells.
We have shown previously that PIST interacts via its PDZ-
domain with the C-terminal part of SSTR5 [12]. C-terminal
interactions of SSTR5 are required to redirect the internalized
SSTR5 back from the Golgi to the plasma membrane; in par-
ticular, overexpression of PIST retains the receptor within the
Golgi-apparatus [12]. The role of PIST in the intracellular
transport of transmembrane proteins extends to other pro-
teins, such as frizzled [13], CFTR [14] and the b1-adrenergic
receptor [15], all interacting with the PDZ-domain of PIST.
PIST modulates intracellular traﬃcking via binding of its
coiled-coil domain to the small GTPase Tc10 [21] and syn-
taxin-6 [22]. Syntaxin-6 is believed to function in the transport
of post-Golgi vesicles to endosomes [23], whereas Tc10 is
known for a role in the transport of secretory vesicles to the
Fig. 2. Analysis of the interaction and subcellular distribution of PIST
and SSTR5. (A) GST fusion protein of the C-terminus of rSSTR5 (R5)
or GST alone (10 lg each) was incubated with glutathione beads and
MIN6 cell lysate. Fractions of the initial (I) and the precipitated
material (P) were analyzed by immunoblotting with anti-PIST
antibody. PIST appears as a double band in precipitates, as described
before [12], possibly due to aggregation. (B–D) MIN6 cells were
treated without (B,D) or with 1 lM SST-28 (C) for 30 min. Cell
homogenates were separated on a discontinous sucrose gradient (0.6–
2.0 M sucrose). Fractions (8 lg protein content) were analyzed by
Western Blotting using the antibodies indicated. Annexin is a marker
for the plasma membrane GM130 for the Golgi, BiP (or GRP78) for
the ER, and Lamp-2 for lysosomes.
Fig. 3. Regulation of PIST protein levels by SST-28. MIN6 cells were
cultured without (control) and with 1 lM SST-28 (SST) for 48 h.
Expression of PIST and BiP (binding protein, also known as GRP78)
in cell lysates was analyzed by immunoblotting (left panel). Protein
expression was quantiﬁed (right panel). Data are means ± S.E.M. for
three independent experiments. \P < 0.05 versus PIST protein levels
under control conditions.
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transport of PIST and its associated CFTR from the Golgi
to the plasma membrane, suggesting that the Tc10/PIST sys-
tem provides a switch, which determines the distribution of
speciﬁc membrane proteins between the plasma membrane
and intracellular compartments.
Here, we show for the ﬁrst time that PIST is expressed in
pancreatic b-cells. We detected PIST in MIN6 cells as well as
in rat islet cells. Subcellular fractionation shows that the
SSTR5 is present at the plasma membrane, while PIST shows
a wider distribution and is detected in the plasma membrane
fraction as well as in the Golgi fractions. After activation of
SSTR5 with its agonist SST-28, the receptor is internalized
into a high-density intracellular compartment, which contains
lysosomes (as well as secretory granules, data not shown).Interestingly, PIST follows SSTR5 and is also internalized into
the same fraction. These data suggest that both proteins form
an intracellular complex located most likely in endosomes/
lysosomes, which is then subjected either to degradation or
recycling back to the plasma membrane. Thus, in b-cells PIST
can control traﬃcking of SSTR5 and thereby surface expres-
sion of the receptor.
The physiological relevance of the PIST–SSTR5 interaction
was assessed by examining insulin secretion in MIN6 cells. As
expected, insulin secretion in MIN6 cells was inhibited by low
concentrations of SST-28. Interestingly, we observed by RT-
PCR analysis that MIN6 cells express a relatively high amount
of endogenous SST (data not shown). Similarly, SST expres-
sion has also been detected in a number of other insulinoma
cell lines [25]. The SSTR5 speciﬁc antagonist BIM23056 en-
hances glucose-induced insulin secretion in the absence of
exogenous somatostatin suggesting that insulin secretion in
MIN6 is regulated in an autocrine manner by endogenous
somatostatin.
Overexpression of PIST renders MIN6 cells more glucose-
responsive and less sensitive to SST-28 inhibition. Inhibition
of SSTR5 signalling with the receptor antagonist and overex-
pression of PIST produce the same functional eﬀects. Consid-
ering that overexpression of PIST reduces the amount of
SSTR5 present at the plasma membrane [13], our data suggest
that MIN6 cells overexpressing PIST also display decreased
SSTR5 levels located on the plasma membrane. Thus, the reg-
ulation of SSTR5 traﬃcking by PIST demonstrated previously
in heterologous expression system contributes to the respon-
siveness of the native receptor in b-cells.
Interestingly, PIST protein expression in MIN6 cells is mod-
ulated by SST. We observed that PIST protein levels were
downregulated after long-term treatment of cells with SST-
28. Internalization of the receptors typically occurs for all
SSTRs after prolonged treatment with agonists. One can spec-
ulate that under the conditions of decreased PIST level induced
by agonist treatment, the internalized SSTR5 will be prevented
from recycling back to the plasma membrane. SSTR5 may be
targeted for degradation in the lysosomes instead. By this
mechanism the cell would impose a constraint on chronic
receptor activation.
Fig. 4. Regulation of insulin secretion by SST-28 and PIST. (A)
Insulin secretion was measured in MIN6 cells after incubation for 1 h
at indicated glucose concentrations and 0 (white bars), 5 (black bars)
or 50 (hatched bars) nM SST-28. Data are means ± S.E.M. for three
independent experiments. \\P < 0.01 and \\\P < 0.001 versus insulin
secretion at the corresponding glucose concentration and no SST-28.
(B) MIN6 cells were transfected with a PIST-EGFP. Insulin and PIST-
EGFP were detected by staining with anti-insulin antibody (left) or the
EGFP-autoﬂuorescence (middle). (C) MIN6 cells were co-transfected
with hGH/EGFP or hGH/PIST-EGFP. After treatment for 1 h with
0 or 20 mM glucose and diﬀerent SST-28 concentrations hGH
secretion was measured and normalized on hGH cellular content.
EGFP transfection: 0 mM glucose, white bars; 20 mM glucose,
black bars. PIST-EGFP transfection: 0 mM glucose, hatched bars;
20 mM glucose, crossed bars. Data are means ± S.E.M. for three
independent experiments. \\P < 0.01 and \\\P < 0.001 versus insulin
secretion at corresponding glucose in cells co-transfected with hGH/
EGFP.
Fig. 5. Eﬀect of SSTR5 antagonist on insulin secretion. Insulin
secretion was measured in MIN6 cells treated for 1 h with 1 lM
BIM23056 (black bars), 50 nM SST-28 and 1 lM BIM23056 (hatched
bars) or without addition of peptides (white bars). Data are
means ± S.E.M. for three independent experiments. \P < 0.05,
\\P < 0.01 and \\\P < 0.001 versus insulin secretion at corresponding
glucose concentration and without peptides.
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